These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 33687868)

  • 1. Expert opinion of the Heart Failure Working Group of the Polish Cardiac Society on the use of dapagliflozin in the treatment of heart failure with reduced ejection fraction.
    Nessler J; Siniarski A; Leszek P; Gumprecht J; Drożdż J; Kaźmierczak J; Witkowski A; Gackowski A; Jankowska EA; Kukulski T; Lelonek M; Rozentryt P; Rubiś P; Ponikowski P;
    Kardiol Pol; 2021 Mar; 79(3):363-370. PubMed ID: 33687868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
    Kato ET; Silverman MG; Mosenzon O; Zelniker TA; Cahn A; Furtado RHM; Kuder J; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Bonaca MP; Ruff CT; Desai AS; Goto S; Johansson PA; Gause-Nilsson I; Johanson P; Langkilde AM; Raz I; Sabatine MS; Wiviott SD
    Circulation; 2019 May; 139(22):2528-2536. PubMed ID: 30882238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dapagliflozin in a Real-World Chronic Heart Failure Population: How Many Are Actually Eligible?
    Maltês S; Cunha GJL; Rocha BML; Presume J; Guerreiro R; Henriques C; Rodrigues C; Araújo I; Fonseca C
    Cardiology; 2021; 146(2):201-206. PubMed ID: 33524984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial.
    Nassif ME; Windsor SL; Tang F; Khariton Y; Husain M; Inzucchi SE; McGuire DK; Pitt B; Scirica BM; Austin B; Drazner MH; Fong MW; Givertz MM; Gordon RA; Jermyn R; Katz SD; Lamba S; Lanfear DE; LaRue SJ; Lindenfeld J; Malone M; Margulies K; Mentz RJ; Mutharasan RK; Pursley M; Umpierrez G; Kosiborod M
    Circulation; 2019 Oct; 140(18):1463-1476. PubMed ID: 31524498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Positive effect of dapagliflozin on left ventricular longitudinal function for type 2 diabetic mellitus patients with chronic heart failure.
    Tanaka H; Soga F; Tatsumi K; Mochizuki Y; Sano H; Toki H; Matsumoto K; Shite J; Takaoka H; Doi T; Hirata KI
    Cardiovasc Diabetol; 2020 Jan; 19(1):6. PubMed ID: 31910853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial.
    Kosiborod MN; Jhund PS; Docherty KF; Diez M; Petrie MC; Verma S; Nicolau JC; Merkely B; Kitakaze M; DeMets DL; Inzucchi SE; Køber L; Martinez FA; Ponikowski P; Sabatine MS; Solomon SD; Bengtsson O; Lindholm D; Niklasson A; Sjöstrand M; Langkilde AM; McMurray JJV
    Circulation; 2020 Jan; 141(2):90-99. PubMed ID: 31736335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of sacubitril / valsartan on the occurrence of ventricular arrhythmia and the risk of sudden cardiac death in patients with chronic heart failure with reduced left ventricular ejection fraction. Expert opinion of the Heart Rhythm and Heart Failure Sections of the Polish Cardiac Society.
    Grabowski M; Ozierański K; Balsam P; Dąbrowski R; Farkowski MM; Gackowski A; Jędrzejczyk-Patej E; Kalarus Z; Leszek P; Nessler J; Sterliński M; Opolski G; Przybylski A
    Kardiol Pol; 2019 Oct; 77(10):987-993. PubMed ID: 31527563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
    Zannad F; Ferreira JP; Pocock SJ; Anker SD; Butler J; Filippatos G; Brueckmann M; Ofstad AP; Pfarr E; Jamal W; Packer M
    Lancet; 2020 Sep; 396(10254):819-829. PubMed ID: 32877652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Dapagliflozin in the prevention and treatment of heart failure].
    Egocheaga I; Escobar C; Pallarés V; Obaya JC
    Semergen; 2021 Dec; 47 Suppl 1():11-17. PubMed ID: 34785155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF).
    McMurray JJV; DeMets DL; Inzucchi SE; Køber L; Kosiborod MN; Langkilde AM; Martinez FA; Bengtsson O; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD;
    Eur J Heart Fail; 2019 May; 21(5):665-675. PubMed ID: 30895697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium-glucose co-transporter-2 inhibitors in the non-diabetic heart failure patient.
    Essa H; Walker L; Sankaranarayanan R
    Br J Clin Pharmacol; 2022 Jun; 88(6):2566-2570. PubMed ID: 34622474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Egyptian expert opinion for the use of sodium-glucose cotransporter-2 inhibitors in patients with heart failure with reduced ejection fraction.
    Abdelhamid M; Kandil H; Hassanin M; Shaheen S; Sobhy M; ElEtreby A; Hasan-Ali H; Mahfouz H; Nasr G; Shawky I; Emil S; ElSetiha M; Hasssan M; Sadek Y; Karim MA; Asham A; Ghaleb M; Samir A; Shokry K
    ESC Heart Fail; 2022 Apr; 9(2):800-811. PubMed ID: 35118822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF.
    McEwan P; Darlington O; McMurray JJV; Jhund PS; Docherty KF; Böhm M; Petrie MC; Bergenheim K; Qin L
    Eur J Heart Fail; 2020 Nov; 22(11):2147-2156. PubMed ID: 32749733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of sodium-glucose co-transporter 2 inhibition according to left ventricular ejection fraction in DAPA-HF.
    Dewan P; Solomon SD; Jhund PS; Inzucchi SE; Køber L; Kosiborod MN; Martinez FA; Ponikowski P; DeMets DL; Sabatine MS; Bengtsson O; Sjöstrand M; Langkilde AM; Anand IS; Bělohlávek J; Chopra VK; Dukát A; Kitakaze M; Merkely B; O'Meara E; Schou M; Vinh PN; McMurray JJV;
    Eur J Heart Fail; 2020 Jul; 22(7):1247-1258. PubMed ID: 32539224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF.
    Inzucchi SE; Docherty KF; Køber L; Kosiborod MN; Martinez FA; Ponikowski P; Sabatine MS; Solomon SD; Verma S; Bělohlávek J; Böhm M; Chiang CE; de Boer RA; Diez M; Dukát A; Ljungman CEA; Bengtsson O; Langkilde AM; Sjöstrand M; Jhund PS; McMurray JJV;
    Diabetes Care; 2021 Feb; 44(2):586-594. PubMed ID: 33355302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of dapagliflozin on ventricular arrhythmias, cardiac arrest, or sudden death in people with heart failure: a tick in another box for sodium-glucose cotransporter 2 inhibitors.
    Koufakis T; Giannakoulas G; Zebekakis P; Kotsa K
    Expert Opin Pharmacother; 2022 Feb; 23(3):321-325. PubMed ID: 34761713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF).
    Jensen J; Omar M; Kistorp C; Poulsen MK; Tuxen C; Gustafsson I; Køber L; Gustafsson F; Fosbøl E; Bruun NE; Videbæk L; Frederiksen PH; Møller JE; Schou M
    Trials; 2019 Jun; 20(1):374. PubMed ID: 31227014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF Trial.
    Solomon SD; Jhund PS; Claggett BL; Dewan P; Køber L; Kosiborod MN; Martinez FA; Ponikowski P; Sabatine MS; Inzucchi SE; Desai AS; Bengtsson O; Lindholm D; Sjostrand M; Langkilde AM; McMurray JJV
    JACC Heart Fail; 2020 Oct; 8(10):811-818. PubMed ID: 32653447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure.
    Seferović PM; Coats AJS; Ponikowski P; Filippatos G; Huelsmann M; Jhund PS; Polovina MM; Komajda M; Seferović J; Sari I; Cosentino F; Ambrosio G; Metra M; Piepoli M; Chioncel O; Lund LH; Thum T; De Boer RA; Mullens W; Lopatin Y; Volterrani M; Hill L; Bauersachs J; Lyon A; Petrie MC; Anker S; Rosano GMC
    Eur J Heart Fail; 2020 Feb; 22(2):196-213. PubMed ID: 31816162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF.
    Docherty KF; Jhund PS; Anand I; Bengtsson O; Böhm M; de Boer RA; DeMets DL; Desai AS; Drozdz J; Howlett J; Inzucchi SE; Johanson P; Katova T; Køber L; Kosiborod MN; Langkilde AM; Lindholm D; Martinez FA; Merkely B; Nicolau JC; O'Meara E; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; Tereshchenko S; Verma S; McMurray JJV
    Circulation; 2020 Oct; 142(17):1623-1632. PubMed ID: 32883108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.